Scipher Medicine, traditionally focused on diagnostics for rheumatoid arthritis, is pivoting toward leveraging its extensive transcriptomic datasets to drive precision medicine beyond oncology. The company is expanding partnerships with pharma and informatics firms to build advanced clinicogenomic platforms, aiming to identify novel biomarkers and support drug development across immunology and other non-oncology fields. This strategy mirrors efforts by industry leaders in oncology, seeking to unravel complex disease mechanisms using large-scale omics data.